However, silencing certain SLC genes (e.g., SLC1A5 in breast cancer and SLC6A14 in colorectal cancer) can significantly impair L‐serine uptake, leading to metabolic disruption, as compensatory changes in other SLCs fail to sustain intracellular L‐serine levels. Here, SLC6A14 is linked to breast cancer.